Comparative Pharmacology
Head-to-head clinical analysis: AVELOX versus TROVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVELOX versus TROVAN.
AVELOX vs TROVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Trovan (trovafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
400 mg orally or intravenously once daily for 7 to 14 days depending on infection severity.
200 mg IV once daily for 7-14 days for community-acquired pneumonia; 200 mg orally once daily for 7-14 days for acute exacerbation of chronic bronchitis
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours) in healthy adults, allowing once-daily dosing. May be prolonged in patients with renal impairment.
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, supporting twice-daily dosing.
Renal (approximately 45-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30% as unchanged drug and metabolites). Total recovery in urine and feces accounts for >96% of the dose.
Renal (approximately 60% unchanged) and fecal/biliary (approximately 35% as unchanged drug and metabolites).
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)